Options for Primary Chemotherapy in Advanced Ovarian Cancer: The European Perspective

Nicoletta Colombo; Aldo Maggioni; M. Vignali; Gabriel Parma; Costantino Mangioni

doi:10.1006/gyno.1994.1348

Related publications

Article1997

Ifosfamide and paclitaxel salvage chemotherapy for advanced epithelial ovarian cancer

Meletios A Dimopoulos, Christos Papadimitriou, C. Gennatas, T. Akrivos, George Vlahos, Zannis Voulgaris, E. Diacomanolis, P. Athanassiades, S. Mihalas

Article2007

Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome.

Eleni Efstathiou, Meletios A Dimopoulos, George Bozas, Efstathios Kastritis, Lia A. Moulopoulos, Alexandros Rodolakis, George Vlahos, Dimitra Gika, Christos Papadimitriou, Aristotelis Bamias

Article2012

Evolving Chemotherapy Options for the Treatment of Myeloma Kidney: A 40-Year Perspective

Efstathios Kastritis, Meletios A Dimopoulos, Joan Bladé

Article2001

Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer

Christos Papadimitriou, Charalambos Kouroussis, Lia A. Moulopoulos, Georgios Vlahos, Alexandros Rodolakis, Christos Kiamouris, Emmanuel Diakomanolis, Dimitra Gika, Stylianos Michalas, Meletios A Dimopoulos

Article2000

Cisplatin, epirubicin and paclitaxel combination chemotherapy in previously untreated patients with advanced epithelial ovarian cancer

Christos Papadimitriou, D. Lazaris, Alexandros Rodolakis, Christos Kiamouris, Georgios M. Gourgoulis, Eleni Galani, E Diakomanolis, S. Michalas, Meletios A Dimopoulos